

Monday, January 19, 2009



HEPATITIS C - Amphitheatre Bleu

8:45

Introduction : Viral Hepatitis in 2009

Patrick Marcellin (France)

9:00 - 10:30

Chairs : Teresa Wright (USA) - Nezam Afdhal (USA)

9:00

■ How to use the virological tools for the optimal follow up of chronic hepatitis C

Jean-Michel Pawlotsky (France)

9:20

■ What are the co-morbidities influencing the management of patients and the response to therapy?

Alfredo Alberti (Italy)

9:40

■ Non invasive fibrosis markers and/or liver biopsy ?

Pierre Bedossa (France)

10:00

■ Round table

All speakers

☕

10:30 - 11:00 ■ COFFEE BREAK

11:00 - 12:30

Chairs : Peter Ferenci (Austria) - Graham Foster (UK)

Optimizing therapy in real life illustrated with clinical cases

11:00

■ Optimal therapy in genotype 1 patients

Stefan Zeuzem (Germany)

11:20

■ Optimal therapy in genotype 2 and 3 patients

Antonio Craxi (Italy)

11:40

■ Optimal therapy in genotype 4 patients

Sanaa Kamal (Egypt)

12:00

■ Round table

All speakers

12:30 - 14:00

Luncheons (details on the central page)

14:00 - 16:00

Chairs : Masao Omata (Japan), Marc Bourlière (France)

14:00

■ Retreatment : who and how ?

Jenny Heathcote (Canada)

14:15

■ New drugs : Enzyme inhibitors

Tarik Asselah (France)

14:30

■ New drugs : Other drugs

Yves Benhamou (France)

14:45

■ What future for ribavirin ?

Mitchel Schiffman (USA)

15:00

■ Round table

All speakers

15:30

■ Clinical case

Eugene Schiff (USA)

☕

16:00 - 16:30 ■ COFFEE BREAK

16:30 - 18:00

Chair : Patrick Marcellin (France)

State of the Art Lecture

16:30

■ The global burden of hepatitis C

Daniel Lavanchy (Switzerland)

1989 -2009 : HCV twenty years later

16:50

■ From B to non B to C : the historical evolution of hepatitis viruses

Harvey Alter (USA)

17:10

■ The HCV Discovery

Michael Houghton (USA)

17:30

■ The history of the « natural history » of hepatitis C

Leonard Seeff (USA)

18:00

■ Awards ceremony

20:00

PROGRAMME OF THE WORKING LUNCHEONS

Regular lunches are also organized in Salons Concorde (Level 4)

HEPATITIS C	Monday, January 19, 2009 • 12:30-14:00
Room 243 1. The burden of hepatitis C in Europe. Epidemiology, actions to increase awareness and access to care. <i>Chairs: Daniel Lavanchy (Switzerland)</i> <i>Speakers: Nikolai Muehlberger (Austria), Philippe Mathurin (France)</i>	
Room 242B 2. Genotype 4: how to treat ? <i>Speakers: Sanaa Kamal (Egypt), Nabil Antaki (Syria)</i>	
Room 242A 3. Clinical Management of hepatitis C in an environment with limited access to treatment <i>Chair: Eugene Schiff (USA)</i> <i>Speaker: Andrzej Horban (Poland)</i>	
Room 241 4. Management of non naive patients with hepatitis C <i>Chair: Alfredo Alberti (Italy),</i> <i>Speakers: Christoph Sarrazin (Germany), Alessandra Mangia (Italy)</i>	
Concorde Room A 5. Management of HIV-HCV co-infected patients <i>Chair: Stanislas Pol (France)</i> <i>Speaker: Jurgens Rockstroh (Germany)</i>	
Concorde Room B 6. French Luncheon : comment prendre en charge les patients atteints d'hépatite C avec les médicaments disponibles dans mon pays. <i>Chair: Daniel Dhumeaux (France)</i> <i>Speakers: Abdellah Essaid El Feydi (Maroc), Saadi Berkane (Algeria)</i>	

HEPATITIS B	Tuesday, January 20, 2009 • 12:30-14:00
Room 241 1. Hepatitis B: predictors and endpoints revisited? <i>Chair: Ferrucio Bonino (Italy)</i> <i>Speaker: Rami Moucari (France)</i>	
Room 242A 2. How to optimize the management of my HBeAg negative patient? <i>Chair: Jean-Pierre Zarski (France)</i> <i>Speaker: Pietro Lampertico (Italy)</i>	
Room 242B 3. End stage HBV-related liver disease: what's left to do? <i>Chair: Massimo Colombo (Italy)</i> <i>Speaker: François Durand (France)</i>	
Room 243 4. How to manage patients with hepatitis B with limited access to care? <i>Chair: Robert Perillo (USA)</i> <i>Speakers: Jidong Jia (China), Vladimir Ivashkin (Russia)</i>	
Concorde Room 5. French Luncheon: comment prendre en charge les patients atteints d'hépatite B avec les médicaments disponibles dans mon pays. <i>Chair: Christian Trépo (France)</i> <i>Speakers: Najet Bel Hadjbrik (Tunisia), Mustapha Bennazouz (Morocco)</i>	

Tuesday, January 20, 2009



HEPATITIS B - Amphitheatre Bleu

8:30 - 10:00		Chairs : Michael Manns (Germany) - Ferruccio Bonino (Italy)	
8:30	■ Natural history of HBV and long-term outcome under treatment	Yun-Fan Liaw (Taiwan)	
8:50	■ How to prevent, diagnose and overcome resistance under nucleos(t)ide analogs ?	Fabien Zoulim (France)	
9:10	■ New endpoints. Back to the future with Australia Antigen ?	Maurizia Brunetto (Italy)	
9:30	■ Round table	All speakers	
 10:00 - 10:30 ■ COFFEE BREAK			
10:30 - 11:30		Chairs : Geoffrey Dusheiko (UK) - Stanislas Pol (France)	
HBeAg-positive chronic hepatitis B			
10:30	■ Why do I treat my patients with nucleos(t)ide analogs ?	Sam Lee (Canada)	
10:45	■ Why do I treat my patients with pegylated interferon ?	George Lau (Hong Kong)	
11:00	■ Round table	All speakers	
11:30 - 12:30		Chairs : Stephanos Hadziyannis (Greece) Jean-Pierre Zarski (France)	
HBeAg-negative chronic hepatitis B			
11:30	■ Why do I treat my patients with nucleos(t)ide analogs ?	Pietro Lampertico (Italy)	
11:45	■ Why do I treat my patients with pegylated interferon ?	Robert Perillo (USA)	
12:00	■ Round table	All speakers	
12:30 - 14:00			
Luncheons (details on the central page)			
14:00		EASL clinical practice guidelines : management of chronic hepatitis B Patrick Marcellin (France)	
14:15 - 15:15		Chairs : Cihan Yurdaydin (Turkey) - Didier Samuel (France)	
14:15	■ Hepatitis B and pregnancy: an underestimated issue	Maureen Jonas (USA)	
14:35	■ Hepatitis D: the come back ?	Mario Rizzetto (Italy)	
14:55	■ Clinical case	Marion Peters (USA)	
15:15 - 16:15		Chairs : Adrian Di Bisceglie (USA) - Raphael Esteban (Spain)	
Hepatocellular carcinoma			
15:15	■ Screening and diagnosis of hepatocellular carcinoma	Massimo Colombo (Italy)	
15:35	■ New drugs for hepatocellular carcinoma	Jordi Bruix (Spain)	
15:55	■ Round table	All speakers	
Conclusion and perspectives :		Patrick Marcellin (France)	
16:15	■ Ajournement		